Please login to the form below
European biotech
This page shows the latest European biotech news and features for those working in and with pharma, biotech and healthcare.
EU identifies first five ‘promising’ COVID-19 drugs as part of therapeutics strategy
This includes Lilly’s bamlanivimab and etesevimab combination, Roche and Regeneron’s REGEN-COV (casirivimab and imdevimab), Celltrion’s regdanivimab and GlaxoSmithKline/Vir Biotech’s sotrovimab. ... The European Medicines Agency (EMA) is
Latest news
-
eureKARE to use $60m financing to bolster next-generation European biotech companies
eureKARE has launched with a $60m Series A financing round to bolster the next-generation of European biotech companies working in the fields of the microbiome and synthetic biology. ... eureKARE has set up biotech start-up studio models – eureKABIOME
-
CureVac and Bayer partner on mRNA-based COVID-19 vaccine
The vaccine also demonstrated early indications of functional T cells, confirming activation of cellular immune response according to the German biotech company. ... The European Commission (EC) has already secured 405 million doses of CVnCoV which will
-
Mega-mergers dominate as buoyant markets lift biopharma
The biotech has also managed to increase its share price since its launch, a feat not frequently achieved in the sector. ... a new surge in confidence in European biotech.
-
Novartis and J&J back latest €400m Medicxi biopharma fund
stage European biotechs, which have tended not have access to as much financial support as their counterparts in the US. ... to Medicxi, with European companies growing in stature and offering improved returns on investment for backers.
-
Illumina sets up first ex-US accelerator site in Cambridge
Boost for UK's golden triangle biotech region. Illumina has set up its first hub for genomics start-up funding outside the US, and has chosen Cambridge in the UK for
More from news
Approximately 22 fully matching, plus 36 partially matching documents found.
Latest Intelligence
-
A snapshot of Healx
Healx is based in Cambridge, UK, a key European biotech hub, and was founded in 2014 by Dr Tim Guilliams, a biochemical engineer and founder of the Cambridge Rare Disease Network, ... Why will the company make it in the high-risk, highly competitive
-
Building European biotech firms to rival those of the US
Germany is European biotech’s sleeping giant. “Germany is Europe’s great untapped player in biotech,” said Richard. ... produced far fewer biotech companies than you would expect, it’s definitely the place to watch.”.
-
European biotech: a new generation of leaders emerges
biotechs’. The growing role of specialist venture capital. One of the key ingredients in these and other recent European biotech success stories is long-term backing from investors. ... European biotech is benefiting from this new support to translate
-
Building Europe’s next breakthrough biotechs
Cambridge's new Biomedical Campus is home to specialist NHS trusts, AstraZeneca's new HQ and biotech firms. ... How can the UK life science ecosystem produce even more biotech start-ups, and propel them to long-term success?
-
25 Women Leaders in UK Healthcare
It’s long been recognised that one of the biggest factors holding back UK and European biotech success has been a paucity of leaders, and that’s why efforts are being ... As well as overseeing the European communications group for Syneos Health, she
More from intelligence
Approximately 2 fully matching, plus 8 partially matching documents found.
Latest appointments
-
Paris biocluster appoints Stéphane Roques as new chief
Former general manager for Emmanuel Macron's party to spearhead Paris' bid to attract life sciences investment
-
Apeiron bolsters management board
With more than 25 years’ experience in initial public offerings, mergers and acquisitions, as well as licensing and financial transactions in the chemical, biotech and pharma industries, Llewellyn-Davies most recently ... He said: “Apeiron is
-
Novimmune expands senior management team
He is currently a board member of German biotech Epiontis, and has previously served as chief financial officer of PregLem and chairman of Aimago. ... Prior to this, Dr Zimmerman was a European biotech analyst at UBS Investment Bank.
-
MRC Technology appoints director of technology transfer
Farquharson is additionally appointed to the EU Commission's Expert Group, advising on the European Biotech Directive's impact on patent law and R&D activities.
-
Creabilis names Catherine Moukheibir as chairman of the board
After an initial career in strategy consulting and investment banking, she held a number of senior management role at European biotech firms including CFO at Movetis, non-executive board member at
More from appointments
Approximately 1 fully matching, plus 5 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Account Exec > CSD – Medical Communications – UK, Lond...
-
Highly Competitive Salary, Bonus &Benefits
- Account Supervisor – Leading Healthcare Advertising Agency – New...
-
Highly Competitive Salary, Bonus &Benefits
- Medical Writers > Scientific Directors – Medical Communicatio...
-
Highly Competitive Salary, Bonus &Benefits
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Senior Medical Writer – Creative Healthcare Advertising – New Yo...
-
Highly Competitive Salary, Bonus &Benefits
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- First trial of a vaccine against Alzheimer’s launches
- Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
- US government to pay $5.3bn for Pfizer‘s Paxlovid
- Roche to present new data for its drug Polivy at the American Society of Hematology’s annual meeting
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- Lucid Group: Orange the World
- First trial of a vaccine against Alzheimer’s launches
- New COVID variant causing concern
- PMEA 2021: A Celebration of Excellence in Patient Engagement
- From Academics to Entrepreneurship: How Tech is Revolutionizing the Diagnostics Landscape
- Impetus Digital wins Canada’s Most Admired Corporate Cultures Awards 2021
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- Biogen’s Aduhelm unlikely to get approval in Europe
- Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
- The pandemic preparedness paradox
- First trial of a vaccine against Alzheimer’s launches
- Good NICE news for Pfizer, but Dendreon drug rejected
PMHub
SEVEN STONES
Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....
Latest intelligence
- Webinar:
- Securing a future for telehealth with immersive market research insights...
- Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
- How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
- Six ways to improve diversity in clinical trials
- Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...
